Zybrivo (sintilimab)

Where it stands

Zybrivo (sintilimab), from Fortvita Biologics (Ireland) Limited, received a positive CHMP opinion on 12 November 2026. The EU record lists its status as "Opinion". No approval date is recorded, so the European Commission (EC) has not yet issued a marketing authorisation according to the data provided.

The indication covered by the record is the treatment of non-squamous non-small cell lung cancer in adults. The therapeutic area is listed as non-small-cell lung carcinoma. The records give no further detail on line of therapy, combination partners or biomarker restrictions, so the exact wording of the indication should be confirmed in the final product information.

Regulatory pathway and designations

A CHMP opinion is the scientific recommendation of the EMA's human medicines committee. It is not itself a marketing authorisation. The EC normally adopts a legally binding decision on the basis of that opinion, and only then can the product be marketed across the EU. The records show Zybrivo has reached the opinion stage and is awaiting that decision.

The only forward-looking milestone is an expected EC decision on 18 January 2027. This is an estimate, not an official date. It is calculated as the CHMP opinion date plus 67 days, the standard Commission decision period. Actual timing can differ.

No designations are recorded for this product. The records therefore show no orphan, PRIME or similar status. They also do not say whether the authorisation is standard, conditional or under exceptional circumstances.

Safety and pharmacovigilance

The records contain no safety data, risk management plan details, additional monitoring status or post-authorisation commitments for Zybrivo, so no safety assessment can be made from them.

What to watch

The main event is the EC decision. The estimated date is 18 January 2027, and the official approval date will replace the current blank field once the decision is issued. A decision date that differs from the estimate would not by itself be informative, because the estimate is a formula and not an official schedule.

After the decision, the final authorised indication, the product information and the conditions of the authorisation should be checked against the CHMP opinion. These details are not in the current records. Anyone planning around this product should rely on official EC and EMA publications for them.